An estimate of the cost of administering intravenous biological agents in Spanish day hospitals
Open Access
- 1 March 2017
- journal article
- research article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 13, 325-334
Abstract
Objective: To estimate the unit costs of administering intravenous (IV) biological agents in day hospitals (DHs) in the Spanish National Health System. Patients and methods: Data were obtained from 188 patients with rheumatoid arthritis, collected from nine DHs, receiving one of the following IV therapies: infliximab (n=48), rituximab (n=38), abatacept (n=41), or tocilizumab (n=61). The fieldwork was carried out between March 2013 and March 2014. The following three groups of costs were considered: 1) structural costs, 2) material costs, and 3) staff costs. Staff costs were considered a fixed cost and were estimated according to the DH theoretical level of activity, which includes, as well as personal care of each patient, the DH general activities (complete imputation method, CIM). In addition, an alternative calculation was performed, in which the staff costs were considered a variable cost imputed according to the time spent on direct care (partial imputation method, PIM). All costs were expressed in euros for the reference year 2014. Results: The average total cost was €146.12 per infusion (standard deviation [SD] ±87.11; CIM) and €29.70 per infusion (SD ±11.42; PIM). The structure-related costs per infusion varied between €2.23 and €62.35 per patient and DH; the cost of consumables oscillated between €3.48 and €20.34 per patient and DH. In terms of the care process, the average difference between the shortest and the longest time taken by different hospitals to administer an IV biological therapy was 113 minutes. Conclusion: The average total cost of infusion was less than that normally used in models of economic evaluation coming from secondary sources. This cost is even less when the staff costs are imputed according to the PIM. A high degree of variability was observed between different DHs in the cost of the consumables, in the structure-related costs, and in those of the care process.Keywords
This publication has 10 references indexed in Scilit:
- Variabilidad en los hospitales de día de Reumatología en España: proyecto VALORAReumatología Clínica, 2017
- Quality Standards in a Rheumatology Day-Care Hospital Unit. The Proposal of the Spanish Society of Rheumatology Day Hospitals’ Working GroupReumatología Clínica (English Edition), 2014
- Estándares de calidad en una Unidad de Hospitalización de Día reumatológica. Propuesta del Grupo de Trabajo de Hospitales de Día de la Sociedad Española de ReumatologíaReumatología Clínica, 2014
- Administration costs of intravenous biologic drugs for rheumatoid arthritisSpringerPlus, 2013
- Modelo de excelencia en el Hospital de Día de Reumatología en España: proyecto HD-ReumatolexReumatología Clínica, 2013
- Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid ArthritisJournal of Managed Care Pharmacy, 2011
- Estado actual de los hospitales de día donde se administran los tratamientos de reumatología en la Comunidad ValencianaReumatología Clínica, 2010
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2010
- Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis.2010
- Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFα biological therapy in FranceJoint Bone Spine, 2005